SCYX Q4 2025 Earnings — SCYNEXIS, Inc. Revenue & Financial Results | Market Cap Arena

SCYXSCYNEXIS, Inc.

$38M

Q4 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$19M+1808.5% YoY

Gross Profit

$00.0% margin

Operating Income

$11M56.4% margin

Net Income

$12M65.7% margin

EPS (Diluted)

$0.28

QoQ Revenue Growth

+5482.6%

Cash Flow

Operating Cash Flow

$18M

Free Cash Flow

$18M

Stock-Based Comp.

$687,000

Balance Sheet

Total Assets

$59M

Total Liabilities

$10M

Stockholders' Equity

$49M

Cash & Equivalents

$21M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$19M	$977,000	+1808.5%
Gross Profit	$0	$977,000	-100.0%
Operating Income	$11M	-$8M	+230.6%
Net Income	$12M	-$4M	+376.5%

Revenue Segments

License and Service

$17M100%